An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action

William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations

Abstract

Angiogenesis is a biologic process whereby endothelial cells divide and migrate to form new blood vessels. This process is required in physiological conditions, but is also a necessary requirement for solid tumors to grow and metastasize. Over the last several years, the growth factors that have both a positive and negative influence on tumor angiogenesis have been delineated. Interfering with tumor angiogenesis was considered a potential therapeutic strategy 25 years ago, but only recently have compounds with an ability to interfere with angiogenesis entered clinical trials. This review will discuss the first generation of angiogenesis inhibitors, their mechanism of action and data from clinical trials.

Original languageEnglish (US)
Pages (from-to)49-59
Number of pages11
JournalInvestigational New Drugs
Volume15
Issue number1
DOIs
StatePublished - Jun 4 1997

Keywords

  • Angiogenesis
  • Inhibitors
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action'. Together they form a unique fingerprint.

Cite this